Transmission-blocking vaccines are based on eliciting antibody responses in the vertebrate
host that disrupt parasite development in the mosquito vector and prevent malaria …

Transmission-blocking vaccines (TBVs), pioneered by Richard Carter and others, aim to
prevent parasite development in the mosquito vector and are a promising new tool for …

Transmission-blocking vaccines have the potential to accelerate malaria parasite
elimination by inducing antibodies that block parasite transmission from humans to …

Abstract Background Transmission-blocking vaccines (TBVs) have become a focus of
strategies to control and eventually eliminate malaria as they target the entry of sexual stage …

Abstract The Plasmodium falciparum Pfs25 protein (Pfs25) is a leading malaria transmission-
blocking vaccine antigen. Pfs25 vaccination is intended to elicit antibodies that inhibit …

Malaria parasite transmission to mosquitoes relies on the uptake of sexual stage parasites
during a blood meal and subsequent formation of oocysts on the mosquito midgut wall …

In the early 1980s, Richard Carter was among the first researchers to identify the sexual
stage-specific Pfs48/45 protein, leading to the identification of target epitopes. Carter …

Transmission-blocking vaccines have the potential to be key contributors to malaria
elimination. Such vaccines elicit antibodies that inhibit parasites during their development in …

A transmission-blocking vaccine (TBV) against Plasmodium falciparum is likely to be a
valuable tool in a malaria eradication program. Pfs230 is one of the major TBV candidates …

Pfs48/45, a member of a Plasmodium-specific protein family, displays conformation-
dependent epitopes and is an important target for malaria transmission-blocking (TB) …